T-1201 which IND application has been approved by US FDA and TFDA and the Phase I clinical trial has been initiated in June, 2021. T-1201
Following IND approval by the US FDA in Mid-January, 2021, Taivex submitted the Phase I clinical trial application to the Taiwan FDA later on January
Taivex received US FDA Investigational New Drug Application (IND) Approval for T-1201 on December 15, 2020, to initiate phase I clinical trial for the treatment
Dr. Lun Kelvin Tsou, associate Investigator of IBPR. Dr, Tsou with his team members had development a noval small molecule drug conjugate, DBPR115, that could
Taivex corporate with Institute of Biotechnology and Pharmaceutical Research (IBPR) at National Health Research Institute, developing a first-in-class small molecule drug, T-1201. This drug had
Taivex Therapeutics Corporation (Taivex) and The National Health Research Institutes (NHRI) are pleased to announce the technology transfer of T-1201 (formerly, DBPR115), a potential anti-cancer
